CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Dexamethasone intravitreal implant

Last Updated: September 1, 2011
Result type: Reports
Project Number: SR0247-000
Product Line: Reimbursement Review

Generic Name: Dexamethasone intravitreal implant

Brand Name: Ozurdex

Manufacturer: Allergan

Therapeutic Area: Macular edema, central retinal vein occlusion

Indications: Macular edema following central retinal vein occlusion

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 25, 2012

Recommendation Type: Do not list